Ken Griffin Rani Therapeutics Holdings, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$2.06 - $3.99 $1,030 - $1,995
500 Added 25.0%
2,500 $5,000
Q2 2024

Aug 14, 2024
SELL
$3.13 - $7.85 $16,902 - $42,390
-5,400 Reduced 72.97%
2,000 $7,000
Q1 2024

May 15, 2024
BUY
$2.98 - $3.8 $22,052 - $28,120
7,400 New
7,400 $23,000
Q2 2023

Aug 14, 2023
BUY
$3.92 - $5.58 $8,624 - $12,276
2,200 Added 220.0%
3,200 $13,000
Q1 2023

May 15, 2023
BUY
$5.07 - $6.89 $5,070 - $6,890
1,000 New
1,000 $5,000

Others Institutions Holding RANI

# of Institutions
35
Shares Held
5.77M
Call Options Held
2.5K
Put Options Held
2.2K
View Full List

About Rani Therapeutics Holdings, Inc.

RANI Quotes by TradingView
  • Ticker RANI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,492,000
  • Market Cap $35.8M
  • Description
  • Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed P...
More about RANI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email